This protocol sets out measures for the follow-up and management of individuals exposed to infected animals and human cases of avian influenza, and for the public health management of possible and confirmed human cases.
In 2020, the European Commission stressed the importance of continuously monitoring the safety and effectiveness of vaccines in the EU/EEA during the post-authorisation phase, with particular emphasis on COVID-19 vaccines in the context of the ongoing pandemic.
This document outlines operational considerations to support the continuity of national surveillance systems and public health laboratories for epidemiological and virological surveillance for influenza, SARS-CoV-2, and potentially other respiratory viruses in the 2022/2023 winter season and beyond.
This study provides insights for national public health authorities into the factors behind the spread of vaccine misinformation online and the options and capacities needed for responding to it.
This report aims to identify and evaluate the operational challenges each country is facing in implementing vector control and to prioritise the needs to be addressed in order to facilitate national public health authorities in developing and/or enhancing their national WNV response capacities.
The influenza vaccination communication guide provide advice, guidance and campaign materials to support national influenza vaccination campaigns with the purpose of increasing the influenza vaccination uptake in the EU Member States.
The aim of this guidance document is to provide EU/EEA Member States and EU bodies with relevant information to make an informed decision on routine vaccination of healthy children and pregnant women with seasonal influenza vaccine. The options presented in this document are based on a systematic review of the literature and the opinions of a group of independent experts.
This first update of the original guide was prompted by the evolution of the Zika virus epidemic, a new classification system for countries/areas, and recent scientific developments.
This ECDC expert opinion confirms earlier assessments by ECDC and national authorities that there is no significant new evidence to support any changes to the approved indications and recommended use of neuraminidase inhibitors (NAIs) in EU/EEA Member States.